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Anthony P HollanderAchieving success in the field of regenerative medicine
will depend in part on our learning how best to manipu-
late cells in vitro in order to elicit therapeutic responses
after implantation into patients. The traditional ap-
proach to tissue engineering is to combine cells with
biomaterial scaffolds in order to create a template for
tissue formation. There is a huge body of literature de-
scribing the science behind this type of approach but
only relatively few clinical trials that shed light on the
feasibility and efficacy of turning this interesting science
into useful medicine [1]. A number of recent clinical
studies have provided important insights into what
might be achieved using a range of different techniques.
Some examples of these are reviewed here in order to
provide an overview of where this young field has got to
and some of the challenges that lie ahead.State of the art in cell therapy
Cell implantation without a supporting scaffold
The treatment of myocardial disease using intracoronary
or intramyocardial bone marrow derived stem cells pro-
vides a fascinating insight into the challenges of using
cell suspensions as drugs. Strauer and Steinhoff recently
reviewed the first 10 years of this novel approach to the
care of patients with heart disease [2]. They describe the
first treatment in 2001 of a patient with a failing left ven-
tricle, using unfractionated mononuclear bone marrow
cells. In 2003 the first attempt was made to use a puri-
fied stem cell fraction [3]. This short report described
the use of an anti-CD133 antibody to isolate bone mar-
row stem cells with potential angiogenic properties. This
was a departure from the original concept of implanting
cells that would restore contractility of the myocardium
and instead focused on restoring the myocardial vascular
supply. However it is becoming apparent that the same
stem cells may both restore contractility (directly or in-
directly) and improve the cardiac circulation [2]. DespiteCorrespondence: A.Hollander@Bristol.ac.uk
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in any medium, provided the original work is pthis lack of clarity on the proposed mechanism of action
of stem cells, the extent of clinical improvement with
these techniques is gradually becoming clear. Clinical
results are highly variable and can be difficult to com-
pare between studies because of huge variations in cell
source, preparation and implantation methodology.
Nevertheless there is merging evidence of a modest but
significant improvement in ventricular performance in
the treatment of acute myocardial infarction and
increased ventricular performance and increased patient
survival in the treatment of chronic infarction [2].
The rapid progression from laboratory to clinic in the
treatment of myocardial disease has not been without
controversy. In a 2004 Nature paper Murray et al pro-
vided evidence to oppose the idea that haematopoietic
stem cells can transdifferentiate into cardiac myocytes
[4]. Murray has publicly debated this issue with Sussman
who is a proponent of the use of bone marrow cells for
heart disease [5]. What is clear is that there is a need to
understand more fully the mechanisms of action of these
cell therapies so that improvements can be made
through selection of cells with the greatest chance of
contributing to the target mechanistic pathways. Itera-
tive loops taking us from the laboratory, into the clinic
and back again to provide increasingly refined cell ther-
apies may be the only way to ensure that we develop ef-
fective and reliable treatments.Cell implantation on synthetic scaffolds
A bewildering array of biomaterials are being developed
as potential scaffolds to combine with cells for tissue en-
gineering [6]. Cells can be delivered on scaffolds to sites
in the body requiring regeneration either as simple cell-
scaffold constructs or after extensive pre-culture in vitro
in order to generate a mature tissue engineered extracel-
lular matrix prior to implantation [7]. Whilst the theory
behind tissue engineering strategies favours a complete
in vitro regeneration approach, the clinical reality is that
investigators have favoured simpler methods involving
delivery of cells within hours or days of seeding ontopen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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may come down to both the high cost of extended cul-
ture periods in a regulated laboratory, the difficulty of
providing evidence of potency and purity when growing
a complex tissue and the challenge of integrating pre-
matured tissue with surrounding natural tissues at the
implantation site. Example clinical studies are discussed
here of cell delivery as a 2-dimensional patch for skin
lesions and as a 3-dimensional implant for urethral
reconstruction.
Moustafa et al have explored the feasibility of treating
diabetic foot ulcers with autologous keratinocytes seeded
onto a medical grade PVC dressing coated with acrylic
acid by the technique of plasma polymerisation [8].
Their report illustrates some of the real difficulties in
designing a clinical trial for tissue engineered products.
Diabetic patients whose foot ulcers were refractory to
conventional therapy were treated with 12 successive
cell-scaffold constructs on a weekly basis. The control
group were treated with cell-free dressings for 6 weeks
and then converted to treatment with 12 cell-loaded
scaffolds. Of the 16 patients originally recruited into the
single-blind controlled trial, only 12 completed the study
for a variety of reasons. There was tantalising evidence
of efficacy, with 4 patients in the treatment group under-
going complete healing, but this effect failed to reach
statistical significance due to the low numbers complet-
ing the study. Furthermore, some of the patients subse-
quently developed second reoccurrence of their ulcers,
raising important questions as to the long-term viability
of this approach.
However Raya-Rivera et al have demonstrated that
meaningful data can be obtained even from an observa-
tional study of new cell therapies [9]. In this elegant study
they treated 5 boys with traumatic urethral injuries with
an engineered urethra. The implants were between 4 and
6 cm in length and were constructed from muscle and
urothelial cells isolated from bladder biopsies and seeded
onto tubularised polyglycolic acid scaffolds. By 3 months,
normal urethra architecture had formed at the repair site.
The boys were followed for up to 6 years after implant-
ation and in all cases there was no need for further clinical
intervention as they all remained continent.
Combination of cells and synthetic scaffold remain a
viable option for developing relatively simple treatments
for complex and intractable diseases.
Cell implantation on decellularised natural tissues
An alternative to the use of cells combined with syn-
thetic scaffolds is the combination of cells with decellu-
larised organs. Under this approach, donated organs are
decellularised in order to render the implant immune-
compatible, avoiding the need for immunosuppressive
therapy. The resulting complex natural scaffold is thenrepopulated with the patient’s own cells, thereby produ-
cing an autologous tissue engineered organ.
In 2008 we used this decellularisation and repopulation
strategy to create the world’s first tissue engineered tra-
chea [10,11], a 6 cm segment of the organ that was
implanted into the left bronchus of a patient with severe
bronchomalacia. The engineered organ was created from
the patient’s own bone marrow derived mesenchymal
stem cells that were expanded to a population of 6 million
and then differentiated along the chondrogenic lineage be-
fore being seeded, in a bioreactor, onto a decellularised
donor trachea from a cadaver. The patient’s own epithelial
cells isolated from an upper airway biopsy were seeded
onto the luminal surface to drive mucosal formation. The
implant remains functional to date showing that by suc-
cessfully replacing the donor cells with the patient’s we
avoided the need for any immunosuppression.
The major question that now needs to be asked of this
decellularisation approach is whether it can help us to
overcome the problem of how to tissue engineer a com-
plex organ. The trachea is a relatively simple tube with
just two cell types. However the approach would be of
most value in complex organ tissue engineering where
synthetic scaffolds are unlikely to be able to provide a
template for complete regeneration. Some fascinating
studies are beginning to show the feasibility of complex
organ regeneration. Ott et al have created bio-artificial rat
hearts by decellularising a donor organ and repopulating
it with a combination of endothelial cells and cardiac pro-
genitor cells [12]. The hearts were maintained in bioreac-
tors and tested for contractile and electrical activity. Some
functional activity was recorded, albeit at a low level com-
pared with natural hearts. In a directly analogous experi-
ment, Soto-Gutierrez et al have decellularised rat liver and
repopulated it with an expanded hepatocyte population
[13]. The repopulated liver tissue showed good cell en-
graftment and good functional hepatic enzyme activity.
We must be cautious not to over- interpret either the
heart or liver tissue engineering studies as they both de-
scribe rat organs in vitro. The engineering of a human
heart or liver would require a much larger cell number
and so probably would be dependent on a good stem cell
source. Furthermore there would need to be evidence of
good efficacy in vivo. However despite these short-
comings, the two studies are encouraging in showing that
decellularisation can be used to produce an extracellular
matrix template with the potential for cell engraftment
and whole organ functionality.
Future challenges
These scientific and clinical breakthroughs are exciting
and show the real potential of cell therapies to cure dis-
eases that were previously untreatable [1]. However
there are several challenges we must overcome if we are
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tine use around the world:
1. Therapeutic profile. Each therapy must have
demonstrable efficacy and have minimal risk of side-
effects. In this respect cell therapies are no different
than drugs. However unlike pharmaceuticals, finding
appropriate pre-clinical models in which to obtain
robust data on efficacy and safety may sometimes be
very difficult [14-16]. The first question will be
which cell type to use for the animal model. If the
intention is to use autologous human stem cells
such as mesenchymal cells, should the pivotal
animal studies be undertaken using human cells in
immune compromised animals or animal cells that
are the nearest equivalent to the human therapeutic?
Similarly, if a human embryonic stem cell is to be
used to generate an implant, should the in vivo
studies use the same human stem cell lines or
equivalent animal stem cells if they are available? A
further difficulty is establishing a safe and effective
dose range for the therapy. This will be easier for
scaffold-free cells that are administered in
suspension as cell number can be varied. Knowing
how to adjust dose in a tissue engineering setting is
more difficult. These issues are not insurmountable
and indeed are being tackled by some research
teams and biotechnology companies. However we
have a long way to go to solve all of the issues.
2. Potential for commercialisation. The most effective
way to make a cell therapy available to large
numbers of patients will be to turn it into a
commercial product that can be distributed world-
wide [17]. This will require each therapy to be cost
effective and simple enough a technology to scale up
for mass-production [18]. For autologous therapies
this will be particularly challenging as a profitable
service-industry model will be required. These issues
may seem profoundly un-academic, but if we fail to
account for this need when developing our new
techniques then the chances of their having a
widespread impact will be much reduced.
3. Regulatory issues. The regulatory environment for
cell therapies is becoming clearer [19,20] but
remains very inconsistent between different
territories. Similarly, there are worldwide variations
in ethical and patenting approaches to cell therapies
that will make successful exploitation of the
emerging science particularly difficult. It is
imperative that laboratory and clinical scientists are
fully up to date with the rules and regulations for
the different types of cell therapy in their own
country and in each of those territories where they
intend to provide access to the treatment.Hope or hype?
The exciting science and early clinical data provide us
with every reason to be hopeful that our young science
will bear fruit and that we will be able to treat many
thousands of patients with cell therapies in the not too
distant future. However we must also recognise the for-
midable hurdles that we must overcome if we are to be
successful in our aims. These hurdles should not stop as
from driving ahead with the translation of the laboratory
techniques into therapeutics but we must underpin all
our work with first rate science that will allow us to ad-
dress the concerns about controlling efficacy and safety.
In addition we must not ignore the commercial and
regulatory issues that will be as important to resolve as
the science. We are indeed on the threshold of a new
age of therapeutics. We should be inspired by the possi-
bility but remain realistic about how quickly we can sat-
isfy the demands of patients for ever-better treatments.
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